Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

L-FBPA showed higher selectivity for L-type amino acid transporter 1: in vitro cellular uptake analysis compared to L-Methionine.

Hayato Ikeda, Tadashi Watabe, Shushi Nagamori, Yoko Tanaka, Pattama Wiriyasermkul, Yasukazu Kanai, Sadahiro Naka, Eku Shimosegawa, Yoshikatsu Kanai and Jun Hatazawa
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1167;
Hayato Ikeda
3Department of Nuclear Medicine and Tracer Kinetics Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadashi Watabe
3Department of Nuclear Medicine and Tracer Kinetics Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shushi Nagamori
1Department of Bio-system Pharmacology Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoko Tanaka
1Department of Bio-system Pharmacology Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pattama Wiriyasermkul
1Department of Bio-system Pharmacology Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasukazu Kanai
2Department of Molecular Imaging in Medicine Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sadahiro Naka
3Department of Nuclear Medicine and Tracer Kinetics Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eku Shimosegawa
2Department of Molecular Imaging in Medicine Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshikatsu Kanai
1Department of Bio-system Pharmacology Graduate School of Medicine, Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Hatazawa
4Department of Nuclear Medicine and Tracer Kinetics Graduate School of Medicine, Osaka University Suita, Osaka Japan
5Osaka University Immunology Frontier Research Center Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1167

Objectives L isomeric form of 4-borono-2-(18) F-fluoro-phenylalanine (L-FBPA) has been reported to show high uptake in the malignant tumors and less physiological accumulation in the normal organs. In this work, we compared the accumulation of L-FBPA and L isomeric form of methionine (L-Met) to evaluate the contribution of L-type amino acid transporter (LAT), focusing on the selectivity between LAT1, which is highly expressed in the many types of malignant tumors, and LAT2, which is mainly expressed in the normal tissue.

Methods In vitro assay was performed using two cell lines: HEK293-hLAT1 (high expression of LAT1) and HEK293-hLAT2 (high expression of LAT2). We evaluated affinity of LATs by uptake inhibitory effects of 14C-leucine for LAT1 and 14C-alanine for LAT2 in the presence of L-FBPA (100 μmol/L), L-Met (100 μmol/L), and control, respectively. Uptake inhibition (%) was defined as the ratio of the test compound uptake to the control uptake, in which lower value indicated high affinity for the corresponding LAT. To evaluate transport capacity of LATs, the efflux analysis was performed by counting the extracellular 14C-leucine for LAT1 and 14C-alanine for LAT2 after the addition of L-FBPA (100 μmol/L), L-Met (100 μmol/L), and control, respectively. Radioactivity counts of 14C-leucine or 14C-alanine were compared by t-test and LAT1 selectivity was defined as the ratio of contribution of LAT1 to that of both LAT1 and LAT2.

Results In the uptake inhibitory tests, L-Met (63.0 ± 3.8%) showed significantly lower uptake compared to L-FBPA (74.9 ± 5.9%) for HEK293-hLAT1 (p < 0.01), and L-Met (50.1 ± 1.8%) showed markedly lower uptake compared to L-FBPA (81.3 ± 6.9%) for HEK293-hLAT2 (p<0.01). In the efflux analysis, no significant difference was observed between L-FBPA (25.3 ± 4.3%/min) and L-Met (25.8 ± 2.9%/min) for HEK293-LAT1, whereas L-Met (36.5 ± 3.4%/min) showed higher transport capacity compared to L-FBPA (24.7 ± 5.3%/min) for HEK293-hLAT2 (p < 0.01). These results suggested that L-Met had high affinity and transport capacity for LAT2, and L-FBPA had higher selectivity of affinity and transport capacity for LAT1 than L-Met.

Conclusions We showed that L-FBPA had higher selectivity for LAT1 compared to L-Met. On the other hand, L-Met had high affinity and transport capacity for LAT2 than L-FBPA, suggesting the possibility of more uptake of L-Met in the non-malignant cells than that of L-FBPA. This study indicated the clinical utility of 18F-FBPA, which can be used for tumor selective PET tracer compared to 11C-Met.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
L-FBPA showed higher selectivity for L-type amino acid transporter 1: in vitro cellular uptake analysis compared to L-Methionine.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
L-FBPA showed higher selectivity for L-type amino acid transporter 1: in vitro cellular uptake analysis compared to L-Methionine.
Hayato Ikeda, Tadashi Watabe, Shushi Nagamori, Yoko Tanaka, Pattama Wiriyasermkul, Yasukazu Kanai, Sadahiro Naka, Eku Shimosegawa, Yoshikatsu Kanai, Jun Hatazawa
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1167;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
L-FBPA showed higher selectivity for L-type amino acid transporter 1: in vitro cellular uptake analysis compared to L-Methionine.
Hayato Ikeda, Tadashi Watabe, Shushi Nagamori, Yoko Tanaka, Pattama Wiriyasermkul, Yasukazu Kanai, Sadahiro Naka, Eku Shimosegawa, Yoshikatsu Kanai, Jun Hatazawa
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1167;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

SPECIAL MTA: Preclinical Probes for Oncology Posters

  • uPAR targeted near infrared guided imaging for resection of primary tumor and metastases in an orthotopic pancreas xenograft model.
  • Development a clinical translatable 68Ga-labeled and GRPR-targeted probe for PET imaging of prostate cancer
  • Folate-PEG-NOTA-Al[18F], an improved PET agent for imaging folate receptor-positive tumors
Show more SPECIAL MTA: Preclinical Probes for Oncology Posters

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire